Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.

HDFN Clinical Trial

Official title:

Clinical Professor of Shanghai Tongji Hospital

Clinical Trial Details — Status: Approved for marketing

Administrative data

• NCT number: NCT02969174
• Other study ID #: ShangjiTongjiHsxk
• Status: Approved for marketing
• Phase: N/A
• First received: November 3, 2016
• Last updated: November 17, 2016

Study information

• Verified date: November 2016
• Source: Shanghai Tongji Hospital, Tongji University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Science and Technology Commission of Shanghai Municipality
• Study type: Expanded Access

Clinical Trial Summary

To establish a genotyping and extraction technology of non invasive prenatal diagnosis for fetal blood group genotype from cell-free fetal DNA in peripheral blood of pregnant women.

To achieve prenatal accurate identification of fetal blood group genotypes，and provide credible theoretical evidence for the prenatal diagnosis and treatment of hemolytic disease of newborn (HDN).

Description:

Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.

Recruitment information / eligibility

• Status: Approved for marketing
• Enrollment: 0
• Gender: Both
• Age group: 12 Weeks to 38 Weeks

Eligibility

Inclusion Criteria:

blood samples of pregnant couples,gender/nation/region is unlimited.

Exclusion Criteria:

adipose or hemolytic samples,overdue samples,unidentified samples

Study Design

N/A

Related Conditions & MeSH terms

• HDFN

Intervention

Other:
• zimin Lu,Guo Sa
chengzhong Liu

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Tongji Hospital, Tongji University School of Medicine